CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 31, 2018--
Therapeutics, Inc., (NASDAQ:MCRB) today announced the appointment of
Eric D. Shaff to the additional role of Chief Operating Officer. Mr.
Shaff has been Executive Vice President and Chief Financial Officer
since joining the Company in November 2014, and he will continue to
retain both positions.
Roger J. Pomerantz, M.D., President, CEO and Chairman of Seres,
commented: “Eric has made outstanding contributions to many aspects of
the Company. In addition to effectively leading Seres’ finance team,
Eric has made key contributions in business development, portfolio
strategy, investor relations and general company operations. During this
period, Seres’ microbiome therapeutics pipeline has substantially
matured, and now includes the SER-109 Phase 3 program for recurrent C.
difficile infection, SER-287 for ulcerative colitis, and SER-262 for
primary C. difficile infection, as well as several preclinical
stage programs, including SER-401 to enhance immuno-oncology checkpoint
inhibitor therapy. As COO, Eric will assist me in leading Seres’
microbiome pipeline candidates toward further late stage development and
“Seres is the leader in the development of microbiome therapeutics, an
entirely new treatment modality with potential to transform many areas
of medicine, and I am delighted to support Seres’ efforts to bring
innovative therapies to patients in need,” said Eric Shaff, Executive
Vice President, Chief Operating Officer and Chief Financial Officer.
Mr. Shaff has served as Seres’ Chief Financial Officer, Executive Vice
President and Treasurer since November 2014. Mr. Shaff also serves on
the Board of Directors for Sigilon Therapeutics and has extensive
experience in the biotechnology field, having worked at Momenta
Pharmaceuticals and Genzyme Corporation, where he was Vice President of
Finance for the Personalized Genetic Health division. Mr. Shaff received
his B.A. from the University of Pennsylvania and his MBA from Cornell
About Seres Therapeutics
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform
company developing a novel class of biological drugs that are designed
to treat disease by restoring the function of a dysbiotic microbiome,
where the natural state of bacterial diversity and function is
imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough
Therapy and Orphan Drug designations from the U.S. Food and Drug
Administration and is in Phase 3 development for multiply recurrent C.
difficile infection. Seres’ clinical candidate SER-287 has
successfully completed a Phase 1b study in patients with
mild-to-moderate Ulcerative Colitis and has obtained Orphan Drug
designation for pediatric Ulcerative Colitis. Seres is also developing
SER-262, the first ever synthetic microbiome therapeutic candidate, in a
Phase 1b study in patients with primary C. difficile infection
and is developing SER-401 to enhance the efficacy of checkpoint
inhibitors in patients with certain tumors.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180131005135/en/
Source: Seres Therapeutics, Inc.
IR or PR Contact
Carlo Tanzi, Ph.D.,
Head of Investor Relations and Corporate Communications